Published in Am J Blood Res on January 17, 2013
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (2013) 4.20
Sumoylation Inhibits the Growth Suppressive Properties of Ikaros. PLoS One (2016) 1.41
Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol (2014) 0.97
Transcriptional regulation of the Ikzf1 locus. Blood (2013) 0.97
Ikaros is absolutely required for pre-B cell differentiation by attenuating IL-7 signals. J Exp Med (2013) 0.95
Ikaros fingers on lymphocyte differentiation. Int J Hematol (2014) 0.94
Loss of B Cells in Patients with Heterozygous Mutations in IKAROS. N Engl J Med (2016) 0.88
Incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia. Haematologica (2013) 0.88
Absence of Genomic Ikaros/IKZF1 Deletions in Pediatric B-Precursor Acute Lymphoblastic Leukemia. Int J Mol Med Sci (2013) 0.80
Constitutive function of the Ikaros transcription factor in primary leukemia cells from pediatric newly diagnosed high-risk and relapsed B-precursor ALL patients. PLoS One (2013) 0.77
Targeting CK2-driven non-oncogene addiction in B-cell tumors. Oncogene (2016) 0.77
Genetically engineered mouse models of human B-cell precursor leukemias. Cell Cycle (2014) 0.76
ARID5B, IKZF1 and non-genetic factors in the etiology of childhood acute lymphoblastic leukemia: the ESCALE study. PLoS One (2015) 0.75
Ikaros' suspended flight in the thymus. Blood (2013) 0.75
Targeting of Heme oxygenase-1 attenuates the negative impact of Ikaros isoform 6 in adult BCR-ABL1-positive B-ALL. Oncotarget (2016) 0.75
Changing of IKZF1 genotype during Philadelphia-negative precursor-B acute lymphoblastic leukemia progression: a short clinical report. Leuk Res Rep (2016) 0.75
Refinement of IKZF1 status in pediatric Philadelphia-positive acute lymphoblastic leukemia. Leukemia (2015) 0.75
Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma. Transl Oncol (2016) 0.75
Ikaros Is a Negative Regulator of B1 Cell Development and Function. J Biol Chem (2016) 0.75
Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia. Haematologica (2017) 0.75
SOX7 promotes the maintenance and proliferation of B cell precursor acute lymphoblastic cells. Oncotarget (2016) 0.75
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25
The Ikaros gene is required for the development of all lymphoid lineages. Cell (1994) 5.90
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. Immunity (1999) 5.50
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22
Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet (2009) 4.47
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell (1995) 4.02
Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity (1996) 3.91
Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71
Genome-wide lineage-specific transcriptional networks underscore Ikaros-dependent lymphoid priming in hematopoietic stem cells. Immunity (2009) 3.18
The Ikaros gene encodes a family of functionally diverse zinc finger DNA-binding proteins. Mol Cell Biol (1994) 3.15
High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia (2007) 2.85
Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment. Science (1992) 2.77
Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits. Immunity (2007) 2.65
LyF-1, a transcriptional regulator that interacts with a novel class of promoters for lymphocyte-specific genes. Mol Cell Biol (1991) 2.41
Regulation of B cell fate commitment and immunoglobulin heavy-chain gene rearrangements by Ikaros. Nat Immunol (2008) 2.40
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood (2006) 2.38
IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia (2010) 2.17
Notch activation is an early and critical event during T-Cell leukemogenesis in Ikaros-deficient mice. Mol Cell Biol (2006) 2.09
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood (2012) 2.09
Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med (2011) 2.04
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol (2009) 2.00
Pre-T cell receptor (TCR) and TCR-controlled checkpoints in T cell differentiation are set by Ikaros. J Exp Med (1999) 1.82
Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med (2009) 1.80
Defects in hemopoietic stem cell activity in Ikaros mutant mice. J Exp Med (1999) 1.76
Predominant interaction of both Ikaros and Helios with the NuRD complex in immature thymocytes. J Biol Chem (2007) 1.76
Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood (2009) 1.64
Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia (2010) 1.57
Cell-autonomous defects in dendritic cell populations of Ikaros mutant mice point to a developmental relationship with the lymphoid lineage. Immunity (1997) 1.56
Widespread failure of hematolymphoid differentiation caused by a recessive niche-filling allele of the Ikaros transcription factor. Immunity (2003) 1.51
IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica (2012) 1.50
Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression. Mol Cell Biol (2010) 1.42
Ikaros represses the transcriptional response to Notch signaling in T-cell development. Mol Cell Biol (2008) 1.33
Ikaros is critical for B cell differentiation and function. Eur J Immunol (2002) 1.32
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia (2011) 1.31
Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica (2012) 1.28
Binding of Ikaros to the lambda5 promoter silences transcription through a mechanism that does not require heterochromatin formation. EMBO J (2001) 1.25
Multiple hematopoietic defects and delayed globin switching in Ikaros null mice. Proc Natl Acad Sci U S A (2002) 1.25
Genetic inactivation of Ikaros is a rare event in human T-ALL. Leuk Res (2009) 1.24
Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group. Leukemia (2004) 1.23
Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia (2010) 1.22
Ikaros is required for plasmacytoid dendritic cell differentiation. Blood (2006) 1.22
Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations. Leukemia (2010) 1.19
STAT5 in B cell development and leukemia. Curr Opin Immunol (2010) 1.19
Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer (2010) 1.18
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. PLoS One (2012) 1.15
Dominant negative isoform of the Ikaros gene in patients with adult B-cell acute lymphoblastic leukemia. Cancer Res (2000) 1.12
Ikaros controls isotype selection during immunoglobulin class switch recombination. J Exp Med (2009) 1.10
Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia. Leukemia (2012) 1.10
Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia. Blood (2011) 1.07
Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations. Leukemia (2012) 1.07
Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia. Cancer Res (1999) 1.03
IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan. Cancer Sci (2011) 1.00
Role of 657del5 NBN mutation and 7p12.2 (IKZF1), 9p21 (CDKN2A), 10q21.2 (ARID5B) and 14q11.2 (CEBPE) variation and risk of childhood ALL in the Polish population. Leuk Res (2011) 0.99
BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene (2006) 0.99
Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases. Leukemia (2012) 0.99
FoxO1 induces Ikaros splicing to promote immunoglobulin gene recombination. J Exp Med (2012) 0.97
Genetic variants modify susceptibility to leukemia in infants: a Children's Oncology Group report. Pediatr Blood Cancer (2012) 0.97
Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia. BMC Genomics (2010) 0.95
Genomic profiling of B-progenitor acute lymphoblastic leukemia. Best Pract Res Clin Haematol (2011) 0.95
Highly sensitive MRD tests for ALL based on the IKZF1 Δ3-6 microdeletion. Leukemia (2011) 0.93
Non-DNA-binding Ikaros isoform gene expressed in adult B-precursor acute lymphoblastic leukemia. Leukemia (2002) 0.92
Role of Ikaros in T-cell acute lymphoblastic leukemia. World J Biol Chem (2011) 0.89
Overexpression of the Ikaros 6 isoform is restricted to t(4;11) acute lymphoblastic leukaemia in children and infants and has a role in B-cell survival. Br J Haematol (2004) 0.84
Overexpression of dominant-negative Ikaros 6 protein is restricted to a subset of B common adult acute lymphoblastic leukemias that express high levels of the CD34 antigen. Hematol J (2003) 0.82
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 19.60
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis (2002) 6.13
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis (2007) 5.15
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis (2006) 4.88
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis (2006) 4.42
Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol (2008) 3.93
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol (2009) 3.38
Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis (2008) 3.18
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol (2009) 2.68
Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood (2005) 2.64
Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid and myelolymphoid lineages. Cell Stem Cell (2007) 2.57
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis (2006) 2.45
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood (2007) 2.36
Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol (2002) 2.31
Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica (2008) 2.20
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Notch activation is an early and critical event during T-Cell leukemogenesis in Ikaros-deficient mice. Mol Cell Biol (2006) 2.09
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood (2005) 1.99
A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells. Nat Immunol (2012) 1.93
Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood (2010) 1.92
MyD88-dependent and -independent murine cytomegalovirus sensing for IFN-alpha release and initiation of immune responses in vivo. J Immunol (2005) 1.92
Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood (2002) 1.83
Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica (2012) 1.80
Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol (2011) 1.80
Identifying infants at high risk of peanut allergy: the Learning Early About Peanut Allergy (LEAP) screening study. J Allergy Clin Immunol (2012) 1.72
Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother (2003) 1.71
MafB restricts M-CSF-dependent myeloid commitment divisions of hematopoietic stem cells. Cell (2009) 1.66
Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL. Blood (2010) 1.60
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys (2011) 1.60
Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. Blood (2013) 1.59
Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. Clin Infect Dis (2009) 1.55
Thymus and mediastinal node involvement in childhood Langerhans cell histiocytosis: long-term follow-up from the French national cohort. Pediatr Blood Cancer (2013) 1.54
A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis (2009) 1.54
Helios deficiency has minimal impact on T cell development and function. J Immunol (2009) 1.50
Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience. Br J Haematol (2013) 1.49
PU.1 determines the self-renewal capacity of erythroid progenitor cells. Blood (2004) 1.48
Changes in causes of death over time after treatment for invasive aspergillosis. Cancer (2008) 1.46
Risk factors for Gram-negative bacterial infections in febrile neutropenia. Haematologica (2005) 1.44
Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother (2011) 1.39
Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep (2004) 1.37
International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother (2010) 1.35
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood (2003) 1.34
Ikaros represses the transcriptional response to Notch signaling in T-cell development. Mol Cell Biol (2008) 1.33
Ikaros is critical for B cell differentiation and function. Eur J Immunol (2002) 1.32
Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica (2011) 1.31
Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer (2006) 1.30
Visualizing PU.1 activity during hematopoiesis. Exp Hematol (2005) 1.28
Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951. Br J Haematol (2011) 1.27
Plasmacytoid dendritic cells are dispensable during primary influenza virus infection. J Immunol (2009) 1.26
Proteomic analysis of malignant lymphocyte membrane microparticles using double ionization coverage optimization. Proteomics (2006) 1.24
Genetic inactivation of Ikaros is a rare event in human T-ALL. Leuk Res (2009) 1.24
Ikaros regulates neutrophil differentiation. Blood (2002) 1.23
Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol (2012) 1.23
Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat Med (2011) 1.23
Laparoscopic partial splenectomy: indications and results of a multicenter retrospective study. Surg Endosc (2007) 1.23
Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis (2006) 1.22
Absence of the steroid receptor coactivator-3 induces B-cell lymphoma. EMBO J (2006) 1.22
Ikaros is required for plasmacytoid dendritic cell differentiation. Blood (2006) 1.22
Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol (2009) 1.20
Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer (2007) 1.19
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther (2003) 1.19
Bcl11b represses a mature T-cell gene expression program in immature CD4(+)CD8(+) thymocytes. Eur J Immunol (2010) 1.18
Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis (2007) 1.17
The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet (2008) 1.16
Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis (2005) 1.15
Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin Cancer Res (2009) 1.12
Disseminated Trichosporon mycotoxinivorans, Aspergillus fumigatus, and Scedosporium apiospermum coinfection after lung and liver transplantation in a cystic fibrosis patient. J Clin Microbiol (2012) 1.11
PU.1: a crucial and versatile player in hematopoiesis and leukemia. Int J Biochem Cell Biol (2007) 1.11
Ikaros controls isotype selection during immunoglobulin class switch recombination. J Exp Med (2009) 1.10
Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. Int J Cancer (2005) 1.10
Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents (2006) 1.10
Helios is associated with CD4 T cells differentiating to T helper 2 and follicular helper T cells in vivo independently of Foxp3 expression. PLoS One (2011) 1.06
The tumor suppressor Ikaros shapes the repertoire of notch target genes in T cells. Sci Signal (2014) 1.06
Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res (2010) 1.05
Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer (2008) 1.03
Successful outcome of treatment of a disseminated infection due to Fusarium dimerum in a leukemia patient. J Clin Microbiol (2002) 1.03
Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis (2003) 1.00
Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab (2009) 0.99
HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol (2007) 0.98
Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis (2005) 0.97
Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clin Infect Dis (2005) 0.97
Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis (2003) 0.96
Ikaros is absolutely required for pre-B cell differentiation by attenuating IL-7 signals. J Exp Med (2013) 0.95
Is pegfilgrastim safe and effective in congenital neutropenia? An analysis of the French Severe Chronic Neutropenia registry. Pediatr Blood Cancer (2009) 0.95
Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis. Neoplasia (2007) 0.95
Early proinflammatory cytokines and C‐reactive protein trends as predictors of outcome in invasive Aspergillosis. J Infect Dis (2010) 0.95
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol (2012) 0.95
An exploratory study of the knowledge, attitudes and perceptions of advance care planning in family caregivers of patients with advanced illness in Singapore. BMJ Support Palliat Care (2012) 0.93
Prognostic significance of allelic imbalance at the c-kit gene locus and c-kit overexpression by immunohistochemistry in pediatric osteosarcomas. J Clin Oncol (2005) 0.93